Novartis has moved a step closer to EU approval of its three-drug asthma therapy Enerzair Breezhaler, and now looks set to beat a rival therapy from GlaxoSmithKline to market. Enerzair (formerly ...
Arizona is suing a major drug maker, accusing it of gaming the system by simply renaming an asthma drug to increase its ...
Shanon and William Schmidtknecht, of Poynette, filed their lawsuit in federal court in Milwaukee on Jan. 21, a year to the ...
The root of the U.S.’s high prescription drug prices lies in its unique system, which allows pharmaceutical manufacturers to ...
GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...
A young Wisconsin man died from an asthma attack after the price of his inhaler skyrocketed nearly $500, according to a lawsuit filed by his family. Cole Schmidtknecht, 22, suffered from asthma ...
A young man with severe asthma used to be able to get his inhaler for cheap, but after UnitedHealthcare's drug arm jacked up the price, he had to go without — and it ultimately killed him ...
Irish biotech GH Research has said the phase 2 win for its inhaled depression drug has “paved the way for future commercial success.” The inhaled mebufotenin candidate, dubbed GH001 ...
“Yesterday there was a kid who came up on the street and said, ‘your music helped me out of a dark place,’” says the Inhaler frontman, piling into none-less-rock’n’roll mineral waters ...
GH Research’s lead molecule, an inhaled 5-MeO-DMT psychedelic named GH001, met its primary endpoint in a mid-stage clinical trial for treatment-resistant depression (TRD), the Dublin-based biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback